Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for trimetazidine, the scientific conclusions are as follows:

Detailed analysis of data shows that during the interval period 25 new cases of “vertigo” were received by the marketing authorisation holder. A total of 86 cases of “vertigo” were reported cumulatively in the post authorisation period, 16 of which were considered serious. A high number of events with a positive dechallenge and some events with a positive rechallenge have been described cumulatively. Although in several “vertigo” cases the confounding factors were identified, the causal role of trimetazidine in 18 out of 86 cases could not be excluded.

As reflected in literature, “vertigo”, in particular in the elderly, might be a predictor of falls, which could be the leading cause of disability. Taking into consideration the above, the product information should be updated to include the risk of “vertigo” with the frequency “not known”.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for trimetazidine the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing trimetazidine is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing trimetazidine are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that such marketing authorisations are varied accordingly.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information **(new text** underlined and in bold**, deleted text ~~strike through~~)**

Summary of Product Characteristics

- Section 4.8

The following adverse reaction should be added under the SOC “Ear and labyrinth disorders” with a frequency “not known”:

“**Vertigo**”

Package Leaflet

4. Possible side effects

Other side effects

Other side effects have occurred in a very small number of people but their exact frequency is unknown:

“**spinning sensation (vertigo)**”

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	March CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	6 May 2017
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	5 July 2017